BPC-157 in Europe: Legal Status Across the EU and UK

BPC-157 has no marketing authorization from the European Medicines Agency or any EU member state. It is not a controlled substance in most European countries, but selling it as a medicine without authorization is illegal across the EU and UK. The rules differ by country, and some nations enforce them more aggressively than others. This BPC-157 Europe guide covers every major jurisdiction.

BPC-157 in the European Union, General Framework

No EMA Marketing Authorization

The European Medicines Agency (EMA) maintains the Union Register of medicinal products (searchable at ec.europa.eu). BPC-157 does not appear in it. No company has applied for centralized marketing authorization through the EMA. Without authorization, BPC-157 cannot be legally marketed as a pharmaceutical product in any EU member state through the centralized procedure.

National Authorization Routes

It is also possible for EU member states to approve pharmaceuticals through national mechanisms (mutual recognition or decentralized). No member states have established national authorization for BPC-157. This suggests that the substance is outlawed from being sold as a medicine in all EU nations through any kind of regulatory process available.

Novel Food Regulation

Under the Novel Food Regulation (EU 2015/2283), any food ingredient without a significant history of consumption in the EU before May 1997 must be authorized before it can be sold. BPC-157 is a synthetic peptide with no history as a food ingredient. It has not been authorized as a novel food. Selling it as a food or dietary supplement in the EU would violate this regulation.

Country-by-Country Status

United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) is the agency that governs the UK’s own regulatory framework which was established after the exit of the country from the EU. BPC-157 does not have an MHRA license (searchable at products.mhra.gov.uk. Despite not being regarded a controlled substance according to the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016, it is allowed to be sold in the UK as a research chemical for laboratory purposes. When it comes to the intentions behind selling BPC-157, there can be consequently legal action for violating the Human Medicines Regulations 2012 if it is sold as a medicine. Whether a sale is regarded as a sale of research chemical or sale of a medicine depends on the marketing information about the product.

Germany

The regulation of pharmaceuticals is done in Germany through the Arzneimittelgesetz that is also known as AMG (German Drug Act). BPC-157 does not have any medicinal product authorization from the BfArM (Federal Institute for Drugs and Medical Devices). Placing an unauthorized medicine on the market is forbidden under Section 21 AMG. The penalties for breach of the law, according to Section 95 AMG, may result in up to three years in jail or a fine. BPC-157 falls outside Schedules I-III of the BtMG (Betäubungsmittelgesetz or Narcotics Act). So it is not categorized as a narcotic drug. However, research exemptions are provided under the AMG Section 73(3) on institutional imports.

France

In France, medicines are regulated by the ANSM (Agence nationale de sécurité du médicament et des produits de santé). There is no marketing authorization for BPC-157 in France. French drug law adheres to the EU framework and has additional provisions for its implementation in France. ANSM has the authority to confiscate unauthorized drugs and punish sellers. In October 2026, we found no ANSM enforcement action against BPC-157.

Netherlands

When it comes to research chemicals, The Netherlands has always been known to be more lenient than many other states in Europe. Although the Dutch Medicines Act prohibits the sale of unapproved pharmaceutical products, there is not as much pressure on suppliers of research chemicals as there is in other European nations, like Germany or France. The case of BPC-157 is also the same, as it has not been endorsed in Holland as a medicine. There are several suppliers of research peptides while functioning from Dutch locations but their absolute legality is still in doubt.

Italy, Spain, Poland

These countries follow the general EU framework. BPC-157 has no national authorization in any of them. Each country's national medicines agency (AIFA in Italy, AEMPS in Spain, URPL in Poland) enforces unauthorized medicine laws within its borders. Enforcement intensity varies. We found no published enforcement actions specific to BPC-157 in these countries as of October 2026.

Sports Ban Applies Across Europe

WADA Code in European Sport

Every country in Europe that recognizes the WADA Code has put the Prohibited List into practice. The use of BPC-157 is listed as an S0 (Non-Approved Substances) at all times, both during and outside of events. All European athletes participating in sports governed by WADA will be subject to the same severe penalties as those everywhere else. Testing and enforcement of regulations are performed by the national anti-doping organizations like the NADA in Germany, AFLD in France, UKAD in Great Britain. For more information on the sanctions put in place and detection, check out our WADA page.

Compounding in Europe

Magistral Preparations

Under European pharmaceutical law, pharmacists who are licenced are allowed to do extemporaneous compounding, which is referred to as "magistral preparations," for each patient individually. Each country has its own methodologies, but the concept is similar to that in the United States, where it is known as 503A. The ability to compound BPC-157 depends, however, on different legal aspects of compounding in various countries. In the majority of European countries, specific substances need to be included in a pharmacopoeia or have been in use as components of already accepted pharmaceutical products. BPC-157 does not meet either criterion in any European country, however.